Blueprint Medicines

Since our founding, we've sustained a focus on advancing female leadership and representation within our walls and in the broader industry. Yesterday, our CEO Kate Haviland joined other female leaders in a panel hosted by The Boston Club, discussing their career paths and the value of diverse perspectives in driving innovation and business success.

Recently, we supported a second seminar to empower the indolent systemic mastocytosis (ISM) patient and caregiver community, in partnership with The Mast Cell Disease Society, Inc., the American Initiative in Mast Cell Diseases, and Medscape/WebMD. Joined by expert speakers across the healthcare and advocacy communities, this session focused on ways to better manage the disease, engage with others impacted by ISM, and make well-informed care decisions backed by education and resources. Read more from #BlueCrew member Paul Lim about the value of collaboration to improve the lives of those impacted by ISM:

While the biopharma industry has extensive research into many common diseases, knowledge gaps persist for rare diseases like systemic mastocytosis (SM). At Blueprint Medicines, we're dedicated to understanding how SM impacts the global patient community. Across Europe, we're working to improve industry awareness of SM, gain insights on patients' experiences, and collaborate with local medical communities and patient organizations. Through our efforts, we aim to increase our impact for more people worldwide.

Over the years, our partnership with Big Brothers Big Sisters of Eastern Massachusetts has provided meaningful opportunities for youth mentorship and learning in biopharma and STEM. This #NationalMentoringMonth, we're proud to be spotlighted in their 2024 Impact Report, showcasing the power of a multi-level collaboration and the ways we support positive outcomes for our local community. Read more: https://lnkd.in/eE-nDGeU

At Blueprint Medicines, we know that professional growth extends beyond our workplace. We encourage employees to expand their knowledge and build their networks, as well as give back to the communities where we live and work. We're proud to spotlight Maria Roche, VP of Clinical Development, for her recent appointments to the Dean’s Board of Advisors at Georgetown University School of Nursing and the Board of Directors at Casa Myrna. With her nursing background and passion for advocacy, Maria is driving impact within our industry, the community and her role at Blueprint. We’re proud to call her #BlueCrew. 

We're proud to be recognized as a 2025 top employer in Switzerland by Top Employers Institute! For the second year running, this award not only validates our commitment to excellence and fostering a supportive workplace, but also motivates us to continue striving for even higher standards in employee satisfaction and organizational culture in Zug and beyond. #TopEmployers2025

At Blueprint Medicines, we're committed to pioneering treatment advances that improve patient outcomes. Our deep understanding of mast cell biology, honed through our work in systemic mastocytosis, has propelled us to advance our research in mast cell disorders. By targeting the KIT receptor—a key regulator of mast cell proliferation, maturation and survival—we aim to unlock new possibilities to address not only the symptoms of allergic and inflammatory diseases but also the underlying biology, striving to make a meaningful difference in patients' lives. Read more in our latest blog: https://lnkd.in/eegK7_7Q

Since our founding, we’ve worked to improve the lives of people impacted by systemic mastocytosis globally. In 2025 and beyond, we're committed to keep driving innovation, supporting optimized diagnostic journeys and care for SM, increasing understanding of the symptom burden, and more. #JPM25 

At #JPM25, we shared positive results from the phase 1 healthy volunteer trial of our wild-type KIT inhibitor, supporting its clinical potential across a range of allergic and inflammatory diseases. These data enable us to plan proof-of-concept studies for multiple diseases in which mast cells play a core role.

Today, we announced our 2025 outlook and strategy for continued growth, leveraging our proven capabilities from research and development to commercialization. Anchored by our systemic mastocytosis expertise and driven by scalable innovation and operational excellence, we aim to transform treatment for many allergic and inflammatory diseases by targeting the mast cell. Our CEO Kate Haviland will present a 2025 company overview at #JPM25 on Monday, January 13. Read more in our press release: https://lnkd.in/e4tNSsib